Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Junshui Ma"'
Autor:
Javier Cortes, Eric P Winer, Oleg Lipatov, Seock‐Ah Im, Anthony Gonçalves, Eva Muñoz‐Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Stephanie Hund, Karina Kulangara, Vassiliki Karantza, Jaime A Mejia, Junshui Ma, Petar Jelinic, Lingkang Huang, Scott K Pruitt, Kenneth Emancipator
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 10, Iss 3, Pp n/a-n/a (2024)
Abstract The efficacy of pembrolizumab monotherapy versus chemotherapy increased with increasing programmed death ligand 1 (PD‐L1) expression, as quantified by combined positive score (CPS; PD‐L1 expression on both tumour cells and immune cells)
Externí odkaz:
https://doaj.org/article/42c035448af94e8fbfc51bd921ef67f3
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/9c4077b1bf964395be555f871ed0eb85
Autor:
Petros Grivas, Blanca Homet Moreno, James Luke Godwin, Mohini Rajasagi, Junshui Ma, Andrey Loboda, Assieh Saadatpour, Jared Lunceford, Razvan Cristescu, Nicholas J. Vogelzang, Jacqueline Vuky, David I. Quinn, Howard Gurney, Winald Gerritsen, Stephane Culine, Toni K. Choueiri, Daniel Castellano, Arjun V. Balar, Dean F. Bajorin, Elizabeth R. Plimack, Thomas Powles, Peter H. O'Donnell, Cora N. Sternberg, Andrea Necchi, Lawrence Fong, Jae-Lyun Lee, Daniel P. Petrylak, Miguel A. Climent, Yves Fradet, Ronald de Wit, Joaquim Bellmunt
Purpose:In an exploratory analysis, we investigated the association between programmed death ligand 1 (PD-L1), tumor mutational burden (TMB), T-cell–inflamed gene expression profile (TcellinfGEP), and stromal signature with outcomes of pembrolizuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4c0b526adf25e6c0a35a819b7ea2c27
https://doi.org/10.1158/1078-0432.c.6532491
https://doi.org/10.1158/1078-0432.c.6532491
Autor:
Petros Grivas, Blanca Homet Moreno, James Luke Godwin, Mohini Rajasagi, Junshui Ma, Andrey Loboda, Assieh Saadatpour, Jared Lunceford, Razvan Cristescu, Nicholas J. Vogelzang, Jacqueline Vuky, David I. Quinn, Howard Gurney, Winald Gerritsen, Stephane Culine, Toni K. Choueiri, Daniel Castellano, Arjun V. Balar, Dean F. Bajorin, Elizabeth R. Plimack, Thomas Powles, Peter H. O'Donnell, Cora N. Sternberg, Andrea Necchi, Lawrence Fong, Jae-Lyun Lee, Daniel P. Petrylak, Miguel A. Climent, Yves Fradet, Ronald de Wit, Joaquim Bellmunt
Supplementary Data from Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d9e78538f697754f5972aaf04722806
https://doi.org/10.1158/1078-0432.22487295.v1
https://doi.org/10.1158/1078-0432.22487295.v1
Publikováno v:
Statistics in Biopharmaceutical Research. 14:523-531
In randomized clinical trials, there has been an increasing interest in identifying subgroups with heterogeneous responses to study treatment based on baseline patient characteristics. Even though the benefit risk assessment of any patient population
Autor:
Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas
Publikováno v:
Clinical Cancer Research, 28, 10, pp. 2050-2060
Clinical Cancer Research, 28(10), 2050-2060. American Association for Cancer Research Inc.
Clinical Cancer Research, 28, 2050-2060
Clinical Cancer Research, 28(10), 2050-2060. American Association for Cancer Research Inc.
Clinical Cancer Research, 28, 2050-2060
Purpose: In an exploratory analysis, we investigated the association between programmed death ligand 1 (PD-L1), tumor mutational burden (TMB), T-cell–inflamed gene expression profile (TcellinfGEP), and stromal signature with outcomes of pembrolizum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9a033eea1a8dbe8ea54e8402e4eed44
https://repository.ubn.ru.nl/handle/2066/250670
https://repository.ubn.ru.nl/handle/2066/250670
Publikováno v:
Statistics in Medicine. 39:4133-4146
In randomized clinical trials with survival outcome, there has been an increasing interest in subgroup identification based on baseline genomic, proteomic markers or clinical characteristics. Some of the existing methods identify subgroups that benef
Autor:
Seock-Ah Im, Karina Kulangara, Shoichiro Ohtani, Vassiliki Karantza, Lingkang Huang, Stephanie Hund, Junshui Ma, Jaime A. Mejia, Oleg Lipatov, Petar Jelinic, Keun Seok Lee, Eva Muñoz-Couselo, Kenneth Emancipator, Laura Testa, Isabell Witzel, Javier Cortes, Peter Schmid, Anthony Gonçalves, Eric P. Winer, Zbigniew Nowecki, Kenji Tamura
Publikováno v:
Pathology. 53:S47-S48
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background PD-L1 is expressed on both tumor and immune cells; however, the mechanism by which PD-L1 modulates the adaptive immune response on tumor versus immune cells may differ. Additionally, the prevalence of PD-L1 expression and the partitioning
Autor:
Rafael Morales-Barrera, Thomas Powles, Mustafa Ozguroglu, Tibor Csoszi, Yohann Loriot, Aude Flechon, Nobuaki Matsubara, Alejo Rodriguez-Vida, Lajos Geczi, Susanna Y. Cheng, Yves Fradet, Stephane Oudard, Seyda Gunduz, Junshui Ma, Mohini Rajasagi, Amir Vajdi, Razvan Cristescu, Kentaro Imai, Blanca Homet Moreno, Ajjai Shivaram Alva
Publikováno v:
Journal of Clinical Oncology. 40:540-540
540 Background: The 3-arm, open-label, phase 3 KEYNOTE-361 study (NCT02853305) evaluated first-line pembro ± chemo vs chemo in advanced UC regardless of PD-L1 status. The trial did not meet its primary end points of superior PFS and OS with pembro +